Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

被引：0

作者：

Rita Nahta

Dihua Yu

Mien-Chie Hung

Gabriel N Hortobagyi

Francisco J Esteva

机构：

[1] Instructor at the Department of Breast Medical Oncology,Departments of Breast Medical Oncology and Molecular & Cellular Oncology

[2] Professor at the Departments of Surgical Oncology and Molecular and Cellular Oncology,undefined

[3] Professor in the Department of Molecular and Cellular Oncology,undefined

[4] Chairman and Professor in the Department of Breast Medical Oncology,undefined

[5] Director of the Breast Cancer Translational Research Laboratory and Associate Professor,undefined

[6] University of Texas MD Anderson Cancer Center,undefined

来源：

Nature Clinical Practice Oncology | 2006年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Despite the impressive results seen in phase II trials of trastuzumab, many tumors that overexpress HER2 show resistance to the drug. Understanding the molecular mechanisms underlying primary or treatment-induced trastuzumab resistance is critical to improving the survival of patients with metastatic breast cancer with aggressive HER2 overexpressing tumors. This review discusses the novel therapeutic strategies that target the aberrant molecular pathways, and explains how these strategies could greatly improve the duration of response to trastuzumab.

引用

页码：269 / 280

页数：11

共 50 条

[31] Combining Multiscale Experimental and Computational Systems Pharmacological Approaches to Overcome Resistance to HER2-targeted Therapy in Breast Cancer
Vaidya, Tanaya R.
Ande, Anusha
Ait-Oudhia, Sihem
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 369 (03): : 531 - +
[32] Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, Eugene R.
Vogel, Charles L.
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 371 - 383
[33] Dual HER2-targeted approaches in HER2-positive breast cancer
Eugene R. Ahn
Charles L. Vogel
Breast Cancer Research and Treatment, 2012, 131 : 371 - 383
[34] HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer
Dekker, Tim Johannes Adrianus
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28)
[35] Late cardiotoxicity related to HER2-targeted cancer therapy
Isabelle Senechal
Maria Sol Andres
Jieli Tong
Ylenia Perone
Sivatharshini Ramalingam
Muhummad Sohaib Nazir
Stuart D Rosen
Nicholas Turner
Alistair Ring
Alexander R Lyon
Cardio-Oncology, 10
[36] PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
Moody, S. E.
Schinzel, A. C.
Singh, S.
Izzo, F.
Strickland, M. R.
Luo, L.
Thomas, S. R.
Boehm, J. S.
Kim, S. Y.
Wang, Z. C.
Hahn, W. C.
ONCOGENE, 2015, 34 (16) : 2061 - 2071
[37] PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
S E Moody
A C Schinzel
S Singh
F Izzo
M R Strickland
L Luo
S R Thomas
J S Boehm
S Y Kim
Z C Wang
W C Hahn
Oncogene, 2015, 34 : 2061 - 2071
[38] Recent advances in HER2-targeted delivery for cancer therapy
Dhritlahre, Rakesh Kumar
Saneja, Ankit
DRUG DISCOVERY TODAY, 2021, 26 (05) : 1319 - 1329
[39] TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer
Mercogliano, Maria F.
De Martino, Mara
Bruni, Sofia
Venturutti, Leandro
Rivas, Martin
Amasino, Matias
Proietti, Cecilia J.
Elizalde, Patricia V.
Schillaci, Roxana
CANCER RESEARCH, 2017, 77
[40] Late cardiotoxicity related to HER2-targeted cancer therapy
Senechal, Isabelle
Andres, Maria Sol
Tong, Jieli
Perone, Ylenia
Ramalingam, Sivatharshini
Nazir, Muhummad Sohaib
Rosen, Stuart D.
Turner, Nicholas
Ring, Alistair
Lyon, Alexander R.
CARDIO-ONCOLOGY, 2024, 10 (01)

← 1 2 3 4 5 →